AI Consensus Investment Thesis
MDT: Medtronic Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Medtronic: 1-Year and 5-Year Forecast Outlook and Rating
Medtronic (MDT) has an immediate Buy & Keep consensus AI recommendation, based on 14 AI analysts.
The 1-year target is $102 for , with +7.79% expected return (+10.01% including net dividends) and a BUY rating.
The 5-year target is $145 for , with +53.23% expected return (+71.06% including net dividends) and a BUY rating.
Latest available market price: USD 94.6, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 2.27%. As of 2026-10-20.
Gross TTM: 3.02% · Two-year annualized gross: 3%.
Tax withholding assumption: 25% (IE). One-off special payments are excluded.
Original published assumption: 2.3% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Medtronic Flagship Insight
Accelerating Clinical Moats Drive Cash Compounding Beyond Bureaucratic Stagnation
High consensus confirms underlying organic growth has inflected toward 7%, driven by pulsed field ablation dominance and non-cyclical demographic demand. Valuation re-rating faces sharp divergence, as 5% Treasury yields, hospital capital rationing, and electrophysiology price wars cap multiple expansion.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Universal Investor (Polymath)
Michael Burry (Vulture)
Elon Musk (Visionary)
Superintelligence (Anthropologist)
Warren Buffett (Value Purist)
Sherlock Holmes (Whistleblower)
Ray Dalio (Strategist)
J.P. Morgan (Titan)
Machiavelli (Insider)
Ran across these frontier AI models
Google Gemini 3.8 Flash
OpenAI GPT-6 Astra
Anthropic Claude Opus 5
Latest published deep-analysis batch. Audit published forecasts in full transparency
Medtronic: forecast questions
What is Medtronic (MDT)'s 1-year price forecast?
Medtronic's 1-year target is $102 for Sept 2027. The current AI rating is BUY. The expected return from the recorded close is +7.79%, or +10.01% modeled return including net dividends. Latest available market price: USD 94.6, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is Medtronic (MDT)'s 5-year price forecast?
Medtronic's 5-year target is $145 for Sept 2031. The current AI rating is BUY. The expected return from the recorded close is +53.23%, or +71.06% modeled return including net dividends. Latest available market price: USD 94.6, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is the return basis?
Latest available market price: USD 94.6, as of 20 Oct 2026. These are model projections, not guaranteed future prices.
How can I compare the AI opinions and audit past Medtronic forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for Medtronic differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Medtronic is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
Medtronic: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in Medtronic at the latest market close (20 Oct 2026): $17,106 by Sept 2031 versus $13,751 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
* Return is calculated incl. 2.3% net dividend yield for Medtronic.
Medtronic's core investment thesis represents an operational transition from conglomerate stagnation to high-margin cash compounding. Underlying organic top-line velocity has inflected to approximately 7%, once adjusted for the 53-week fiscal distortion, propelled by rapid adoption of Affera Sphere-9 pulsed field ablation, Evolut FX+ valves, and renal denervation. The strategic separation of the capital-intensive MiniMed diabetes unit retires approximately 4% to 5% of outstanding equity while structurally eliminating margin-dilutive overhead. Crucially, trailing free cash flow of $6.13 billion establishes a 5.2% cash yield that fully underwrites progressive dividend commitments and internal R&D. Valuation sensitivity remains acutely anchored to the sovereign macro backdrop. With benchmark 10-year Treasury yields near 5%, equity discount rates harshly penalize long-duration cash flows, preventing a return to historical peak multiples above 25 times earnings. Furthermore, aggressive commercial counterattacks from incumbent peers will inevitably erode electrophysiology catheter pricing power. Consequently, shareholder value must be generated primarily through earnings compounding, operational leverage from manufacturing footprint consolidation, and share retirement rather than speculative multiple expansion.
Key insights
- Pulsed field ablation shifts electrophysiology revenue from cyclical equipment sales to high-margin recurring catheter pull-through, systematically expanding cardiovascular gross margins.
- MiniMed's tax-free split-off functions as a discounted share repurchase, permanently lifting per-share intrinsic owner earnings without deploying liquid balance-sheet reserves.
- Restrictive sovereign borrowing costs constrain hospital capital budgets, enforcing flexible robotic leasing models and shifting economic returns onto single-use consumables.
Medtronic: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 94.6, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 2.27%. As of 2026-10-20.
Gross TTM: 3.02% · Two-year annualized gross: 3%.
Tax withholding assumption: 25% (IE). One-off special payments are excluded.
Original published assumption: 2.3% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at USD 92.1. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Evidence-Weighted Consensus Price Path | Individual Advisor Range & Reference Forecasts | ||||||
|---|---|---|---|---|---|---|---|---|
| Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) | |
| $94.4 | +2.47% | -0.24% | +0.12% | The MiniMed split-off exchange offer concludes, retiring roughly 4% of parent shares. Sustained double-digit electrophysiology volume growth counters elevated Treasury yields, allowing per-share cash accretion to produce a measured initial valuation advance. | $90.3 | $96.7 | $750 | |
| $97.0 | +2.76% | +2.50% | +3.45% | Third-quarter results demonstrate underlying organic demand holding near 7% after stripping out calendar distortions. Expanding commercial coverage for renal denervation procedures and steady cardiac pacing replacements reinforce confidence, prompting steady institutional accumulation. | $93.9 | $101 | $736 | |
| $99.5 | +2.56% | +5.15% | +6.71% | Fiscal 2027 closes with solid earnings, but forward fiscal 2028 guidance reveals optical revenue contraction from diabetes deconsolidation. Resilient consumable cash flows prevent severe drawdowns, though headline-driven allocator caution temporarily caps quarterly performance. | $93.9 | $107 | $743 | |
| $102 | +2.39% | +7.79% | +10.01% | Initial post-split reporting clarifies underlying operating margin expansion and higher revenue quality. Sustained international Affera catheter pull-through dispels deceleration fears, prompting sell-side margin upgrades and renewed upward valuation momentum. | $95.8 | $110 | $755 | |
| $105 | +2.91% | +10.96% | +13.88% | Manufacturing efficiency gains and cleanroom automation begin lowering unit production costs across cardiovascular product lines. High-margin disposable catheter utilization accelerates, translating volume growth into positive operating leverage and steady equity gains. | $97.8 | $114 | $776 | |
| $107 | +1.62% | +13.07% | +16.70% | Hospital capital budget tightening and seasonal respiratory pressures temporarily moderate large-scale equipment installations. However, non-deferrable chronic implant procedures cushion cash flow, keeping equity pricing resilient despite selective competitive discounting in electrophysiology. | $98.7 | $117 | $787 | |
| $110 | +3.30% | +16.24% | +20.65% | Full-year fiscal 2028 earnings validate structural operating margins exceeding 18.5%. Cash generation comfortably funds the 51st consecutive annual dividend increase, attracting defensive institutional capital seeking dependable yields amid late-cycle macroeconomic deceleration. | $102 | $122 | $803 | |
| $112 | +1.95% | +18.36% | +23.54% | Spine navigation integration and cranial technology suites drive steady surgical implant cross-selling. Incremental procedural adoption offsets Section 301 component tariff friction, supporting stable earnings visibility and moderate share price compounding. | $102 | $126 | $812 | |
| $115 | +2.59% | +21.53% | +27.56% | Outpatient renal denervation adoption broadens across commercial payers, scaling cath-lab procedure volumes. Favorable therapeutic mix and maturing manufacturing lines lift free cash flow conversion, reinforcing market perception of genuine operational turnaround. | $104 | $131 | $839 | |
| $117 | +1.87% | +23.64% | +30.50% | Rival medtech entries in pulsed field ablation trigger competitive pricing friction across European accounts. Procedure volumes continue expanding, but narrower catheter average selling prices moderate incremental operating leverage, leading to modest consolidation. | $102 | $134 | $851 | |
| $120 | +2.22% | +26.81% | +34.60% | Fiscal 2029 results highlight robust trailing free cash flow exceeding $6.8 billion. Operating expense discipline successfully absorbs international volume-based procurement cuts, enabling opportunistic anti-dilutive share repurchases that support per-share intrinsic value. | $104 | $140 | $872 | |
| $122 | +1.83% | +28.92% | +37.62% | Scheduled manufacturing facility consolidations and plant rationalizations generate permanent structural cost savings. Non-cyclical demographic demand for structural heart implants buffers broader economic weakness, ensuring dependable defensive financial performance. | $105 | $145 | $886 | |
| $125 | +2.77% | +32.09% | +41.80% | Second-generation pulsed field ablation catheters and navigation software integrations launch globally. Enhanced clinician retention and recurring consumable reorders re-accelerate cardiovascular margins, driving positive institutional sentiment and solid quarterly appreciation. | $107 | $149 | $910 | |
| $128 | +1.74% | +35.26% | +46.00% | Higher-for-longer sovereign interest rates continue capping valuation multiple expansion across large-cap medtech. Nevertheless, disciplined working capital management and steady neurostimulation replacement cycles ensure resilient cash compounding without balance-sheet strain. | $107 | $152 | $916 | |
| $131 | +2.47% | +38.43% | +50.27% | Fiscal 2030 financial disclosures demonstrate adjusted operating margins approaching 20% on the optimized post-separation portfolio. Strong free cash flow conversion reinforces dividend aristocrat positioning, underpinning durable mid-single-digit shareholder returns. | $109 | $158 | $937 | |
| $133 | +1.86% | +40.55% | +53.43% | Seasonal summer surgical moderation slightly tempers quarterly revenue velocity. Established enterprise hospital bundling contracts and steady cardiac pacing implants protect baseline operating profits, preserving recent valuation gains. | $110 | $163 | $947 | |
| $136 | +2.40% | +43.72% | +57.77% | Matured renal denervation and robotic surgical instrumentation cohorts deliver consistent, high-margin consumable annuities. Broadening international procedures cushion domestic pricing scrutiny, sustaining steady per-share cash flow expansion and upward price tracking. | $111 | $168 | $970 | |
| $139 | +1.57% | +46.89% | +62.14% | Pricing pressures in standardized vascular commodities are fully mitigated by high-volume transcatheter aortic valve deployments. Investors value the franchise as an essential healthcare compounder, supporting share prices through steady operational execution. | $111 | $171 | $980 | |
| $142 | +2.46% | +50.06% | +66.58% | Fiscal 2031 results mark the completion of a five-year turnaround, with annual free cash flow approaching $7.5 billion. Expanding owner earnings and disciplined balance sheet deleveraging validate the long-term margin recovery thesis. | $113 | $178 | $1,000 | |
| $145 | +1.85% | +53.23% | +71.06% | The forecast horizon closes with valuation anchored by durable cash compounding and disciplined share count reduction. Structural procedure growth across an aging global population secures steady terminal cash generation. | $115 | $183 | $1,012 | |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Medtronic Stock Analysis & Scenarios Deep Dive
Medtronic: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Prevailing market consensus treats the enterprise as a lumbering, low-beta dividend utility trapped in historical 3% to 4% organic growth. Investors anchor on past execution slips, hospital capital equipment freezes, and headline calendar distortions, viewing recent revenue acceleration as a transitory artifact. Consequently, the crowd prices the business at an undemanding multiple, heavily discounting management's margin turnaround narrative and treating competitive share erosion as permanent.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates value due to an analytical blind spot regarding underlying operational momentum. Consensus mistakenly dismisses Q1 fiscal 2027 performance as mere calendar noise, overlooking that organic growth reached 7% led by an 88% surge in cardiac ablation. Furthermore, the market fails to price the EPS accretion of retiring 4% to 5% of parent equity via the MiniMed split-off. This disconnect offers an attractive margin of safety anchored by a 5.2% free cash flow yield.
Repricing Catalyst
What could make the market recognize and close that gap? Completion of the MiniMed share exchange offer in late 2026, followed by consecutive ordinary-length quarterly prints confirming sustained 6.5%+ organic top-line growth, will close the gap. As reported operating margins approach 19% without diabetes dilution, sell-side analysts will be forced to lift forward earnings estimates throughout fiscal 2027 and 2028, compelling institutional rotation into the shares.
Medtronic: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Fear
- Volatility Regime
- Moderate
- Convergence Cycle Position
- Growing Awareness
Sentiment reflects tension between deep skepticism regarding historical conglomerate bureaucracy and growing institutional recognition of operational acceleration. Disagreement centers on whether high interest rates permanently cap equity multiples or merely delay an aggressive multiple re-rating.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop represents a mixed setup. Benchmark 10-year Treasury yields near 5% and restrictive central bank policy impose duration-driven multiple compression and lengthen hospital capital equipment sales cycles. However, non-discretionary clinical procedural demand exhibits near-total economic inelasticity, insulating surgical implant volumes, cash collection, and debt service from consumer slowdowns.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive disagreement across reports centers on terminal valuation multiples and operational execution speed. Growth-oriented views argue that pipeline breakthroughs in pulsed field ablation and robotics justify aggressive multiple expansion toward 20 to 24 times earnings. Conversely, skeptical frameworks insist that 5% benchmark bond yields, hospital capital freezes, and bureaucratic inertia will cap multiples near 15 to 16 times, limiting appreciation strictly to organic cash flow compounding. Resolving this tension requires tracking ordinary-length quarterly organic growth without calendar distortions and monitoring electrophysiology gross margins against competitive pricing pressure.
Medtronic: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Pulsed field ablation portfolio scale | Innovation And Product | +20% | +22% | Commercial adoption of the Affera mapping system and PulseSelect catheter is transforming electrophysiology, delivering 88% growth in cardiac ablation. This technology converts installations into recurring, high-margin consumable catheter revenue. Installed-base expansion captures procedure share from thermal ablation, driving sustained cardiovascular margin accretion and lifting earnings over the five-year forecast horizon. |
| Inelastic demographic surgical demand | Sector And Industry | +14% | +14% | Aging global demographics generate non-discretionary procedural volume for transcatheter aortic valves, leadless pacemakers, and neurostimulation devices. Non-deferrable chronic disease interventions insulate Medtronic from cyclical economic downturns. This biological volume momentum underpins reliable mid-single-digit organic top-line expansion and defensive operational cash generation exceeding $6 billion annually. |
| MiniMed split-off per-share accretion | Capital Allocation | +13% | +10% | Separating the capital-intensive diabetes unit via an equity exchange offer retires an estimated 4% to 5% of outstanding parent shares at a discount. This portfolio pruning eliminates margin-dilutive hardware manufacturing, reduces dividend payout liabilities, and sharpens return on invested capital, immediately lifting structural earnings per share. |
| Manufacturing rationalization and operating leverage | Operational Efficiency | +11% | +14% | Aggressive supply-chain consolidation, plant footprint rationalization, and automated cleanroom manufacturing are reversing post-pandemic cost bloat. Operating margins stabilized at 17.8% and possess a viable path toward 20% as commercial launches mature. Cost absorption allows incremental revenue to flow directly into expanding free cash flow per share. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Restrictive sovereign yield multiple ceiling | Macroeconomic And Macrofinancial | -9.0% | -4.0% | Benchmark 10-year Treasury yields hovering near 5% and central bank policy rates around 4% exert relentless downward gravity on equity valuation multiples. High risk-free yields make Medtronic's 3% dividend yield and 5.2% cash yield relatively less compelling, strictly capping multiple expansion and forcing total returns to rely entirely on earnings growth. |
| Hospital capital budget tightening headwinds | Macroeconomic And Macrofinancial | -8.0% | -7.0% | Elevated borrowing costs and tight healthcare operating margins force hospital procurement committees to ration capital expenditure. Healthcare networks defer large purchases of Hugo surgical robotic towers and advanced imaging consoles. This institutional capital rationing lengthens sales cycles, compressing upfront capital equipment revenue and slowing high-margin instrument utilization. |
| Intense electrophysiology competitive pricing warfare | Competitive Positioning | -7.0% | -8.0% | Well-capitalized peers, notably Boston Scientific and Abbott, are defending cath-lab market share through aggressive pricing and bundled contracts. As pulsed field ablation catheters proliferate, hospital purchasing consortiums demand deeper discounts. This rivalry forces elevated marketing expenses, compressing catheter average selling prices and limiting incremental gross profit expansion. |
| Global procurement price compression | Regulatory | -7.0% | -8.0% | Expanding centralized volume-based procurement across China and mandatory budgetary reimbursement caps in European single-payer systems enforce statutory price cuts on mature devices. These administrative price reductions inflict steady headwinds on mature cardiac pacing and spinal hardware lines, offsetting premium pricing gains achieved in advanced therapeutic categories. |
Medtronic: What Could Break or Accelerate the Thesis
Event Risk Score: Very Low 3/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Flagship implant Class I safety recall | 21% | -22% | A systemic hardware defect, dielectric breakdown, or battery failure across core pulsed field ablation or leadless pacemaker lines triggering an FDA Class I recall would be devastating. Beyond remediation expenses exceeding $1 billion, procedural halts and clinician defections to rival platforms would permanently impair cardiovascular earnings power. |
| Sovereign healthcare mandatory payment reset | 24% | -17% | Severe fiscal deficits forcing US legislative expansion of mandatory reimbursement price cuts across inpatient physician-preference implantable devices would crush hospital economics. Forcing statutory discounts on pacemakers, valves, and neuromodulation hardware would compress gross margins below 60%, precipitating earnings contractions and multiple de-rating across medtech. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Renal denervation reimbursement floodgate opening | 34% | +21% | CMS establishing broad, permanent outpatient reimbursement alongside synchronized private payer coverage for Symplicity Spyral by 2028 would unlock a multi-billion-dollar market. Treating millions of uncontrolled hypertensive patients would accelerate corporate organic revenue growth above 8%, generating high-margin catheter cash flows and driving multiple expansion. |
| Hugo robotic multi-specialty FDA clearance | 29% | +18% | Securing unencumbered FDA 510(k) clearances for the Hugo robotic system in high-volume general surgery and gynecology before 2028 would break Intuitive Surgical's near-monopoly. Capturing substantial soft-tissue procedure volume would drive high-margin recurring instrument and stapler pull-through, lifting operating margins beyond 21% and boosting valuation. |
Company Financial AnalysisMedtronic: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest Medtronic financials here.
Earnings and financials
Medtronic's financial results demonstrate an unmistakable shift from multi-year stagnation toward authentic operational acceleration. For fiscal 2026, reported revenue expanded 8.4% to $36.4 billion, and the momentum continued into the first quarter of fiscal 2027 with reported organic growth of 13.7%. While an extra selling week flattered that headline figure, underlying growth remained solid at roughly 7%, spearheaded by an extraordinary 88% surge in cardiac ablation solutions. Crucially, this top-line resurgence is backed by genuine cash generation rather than accounting gimmicks. Trailing free cash flow reached $6.13 billion, comfortably funding $3.64 billion in annual dividend payments while supporting disciplined share buybacks. As high-margin procedural consumables outpace capital equipment sales, earnings quality is steadily improving across core divisions.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2026 | USD 36.4B | USD 4.8B | USD 5.4B |
| 2025 | USD 33.5B | USD 4.7B | USD 5.2B |
| 2024 | USD 32.4B | USD 3.7B | USD 5.2B |
| 2023 | USD 31.2B | USD 3.8B | USD 4.6B |
| 2022 | USD 31.7B | USD 5B | USD 6B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2026 | 21.7x | TTM | Native | USD / USD |
| 2025 | 23.4x | TTM | Native | USD / USD |
| 2024 | 28.1x | TTM | Native | USD / USD |
| 2023 | 32.2x | Annual | Native | USD / USD |
| 2022 | 27.6x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Profitability margins are establishing a durable floor after absorbing years of post-pandemic supply-chain inflation and tariff expenses. Gross margin held steady at 65.0% in fiscal 2026, while operating margin improved to 17.8%. In the first quarter of fiscal 2027, net income jumped 41% as manufacturing efficiencies and favorable procedural mix took hold. This margin recovery reflects structural improvements rather than temporary cost-cutting. Premium pulsed field ablation catheters command higher profitability than older thermal tools, while shedding the lower-margin diabetes division will immediately lift consolidated margins. As automated factory production expands, operating margins possess a clear pathway toward 20% over the next several years.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2026 | USD 6.5B | 17.8% | 13.2% |
| 2025 | USD 6B | 17.8% | 13.9% |
| 2024 | USD 5.1B | 15.9% | 11.4% |
| 2023 | USD 5.5B | 17.6% | 12.0% |
| 2022 | USD 5.8B | 18.2% | 15.9% |
Balance sheet and leverage
Medtronic operates from a conservative financial position designed to navigate restrictive interest rate environments smoothly. The company closed fiscal 2026 with $93.0 billion in total assets against $49.5 billion in shareholder equity, resulting in a prudent debt-to-equity ratio of 0.57. Manageable debt servicing is underscored by an interest coverage ratio of 9.6 times. While gross debt stands near $28 billion and historical acquisitions leave substantial intangible assets on the books, robust operating liquidity and a current ratio of 2.13 provide substantial protection. Generating over $6 billion in annual free cash flow ensures Medtronic can easily service its obligations and sustain dividend increases without needing external borrowing.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2026 | USD 28B | USD 9.2B | USD 26B net debt | USD 18.7B | 2.13x |
| 2025 | USD 28.5B | USD 9B | USD 26.3B net debt | USD 19.6B | 1.85x |
| 2024 | USD 25B | USD 8B | USD 23.7B net debt | USD 17B | 2.03x |
| 2023 | USD 24.4B | USD 8B | USD 22.8B net debt | USD 16.4B | 2.39x |
| 2022 | USD 24.1B | USD 10.6B | USD 20.4B net debt | USD 13.5B | 1.86x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Management is exercising tight capital discipline, maintaining capital expenditures at a modest 5.2% of revenue while directing $2.87 billion annually into targeted research and development. Rather than chasing expensive, dilutive mega-acquisitions, capital is deliberately focused on automated cleanrooms, precision tooling, and clinical regulatory trials for high-margin catheters and robotics. The most decisive capital allocation move is subtractive: spinning off the capital-intensive diabetes unit. Exiting pump manufacturing eliminates a business with high research requirements, freeing up financial resources for cardiac ablation and soft-tissue surgery. This selective reinvestment posture optimizes returns on invested capital and preserves strong cash conversion.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2026 | USD 1.9B | USD 2.9B |
| 2025 | USD 1.9B | USD 2.7B |
| 2024 | USD 1.6B | USD 2.7B |
| 2023 | USD 1.5B | USD 2.7B |
| 2022 | USD 1.4B | USD 2.7B |
Behind the synthesisMedtronic: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
The independently supported consensus reveals an operational inflection in underlying organic revenue growth toward 6% to 7%, led by rapid pulsed field ablation adoption and resilient non-cyclical procedural demand. Multiple reports correlate by projecting substantial valuation re-rating; however, rigorous scrutiny proves multiple expansion is severely constrained by benchmark sovereign bond yields hovering near 5% and persistent tariff frictions. Heaviest weighting is awarded to analyses grounded in primary SEC filings, which correctly adjust Q1 fiscal 2027 performance for the 53-week calendar effect and model the MiniMed split-off as a share-count retirement rather than free cash infusion. Credible contrarian reasoning identifying hospital capital budget rationing, slow surgical robotics adoption, and inevitable electrophysiology catheter price erosion is preserved to counterbalance aggressive growth forecasts. Unsupported claims of dramatic multiple expansion toward historical zero-rate peaks are downweighted, grounding the consensus in cash-flow compounding and margin recovery.
All 14 opinions
Universal Investor AI
The Polymath
Anthropic Claude Opus 5 · 2026-07-24 releaseWeight: 13.3%
Exemplary primary evidentiary grounding across regulatory filings and exchange offer mechanics. It correctly deconsolidates diabetes revenue, isolates the 53-week calendar effect, and rigorously articulates how tariff friction and sovereign yields cap multiple expansion while earnings compound.
Universal Investor AI
The Polymath
OpenAI GPT-6 Astra · 2026-09-03 releaseWeight: 11.4%
This analysis provides rigorous primary source verification across SEC filings and clinical notices. It properly adjusts reported Q1 growth for the extra selling week and treats MiniMed separation economics realistically. Its valuation cross-check against benchmark bond yields anchors prudent baseline compounding.
Ray Dalio AI
The Strategist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.6%
Presents strong macroeconomic causal framing contrasting late-cycle sovereign debt yields with inelastic procedural demand. The rationale incisively details per-share accretion from the MiniMed exchange offer, though it slightly downplays persistent competitive pricing pushback in electrophysiology.
Elon Musk AI
The Visionary
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.6%
Delivers an essential contrarian critique highlighting corporate bureaucratic inertia, surgical robotics commercialization lag, and hospital capex impasses. While its organic growth forecast of 5.5% is excessively punitive, its skepticism on multiple expansion provides a vital ballast.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.7%
Sound long-term owner orientation focused on durable procedural moats and free cash flow generation. However, it lacks primary research source citations and models multiple expansion too optimistically despite acknowledging hospital capital budget rationing headwinds.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.7%
Offers solid reasoning regarding supply-chain rationalization and manufacturing leverage. Nevertheless, it accepts headline revenue acceleration without adjusting for calendar distortions and unconvincingly assumes multiple re-rating to 25 times earnings in a restrictive interest rate environment.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.7%
Accurately maps the clinical reimbursement opportunity for renal denervation alongside solid balance sheet metrics. It lacks specific SEC source citations and treats the diabetes separation merely as an upside tail option rather than an ongoing corporate action.
Michael Burry AI
The Vulture
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.7%
Provides sharp forensic insights into plant rationalization, footprint exits, and activist governance influence on margins. It models steep multiple re-rating without thoroughly accounting for electrophysiology catheter average selling price erosion from competing platforms.
Sherlock Holmes AI
The Whistleblower
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.7%
Accurately normalizes Q1 organic top-line velocity and highlights capital-light console placement dynamics. However, it relies heavily on unmodeled forward multiple re-rating and overlooks transition service liabilities following the diabetes unit separation.
Niccolo Machiavelli AI
The Insider
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.7%
Strong analysis of institutional coding durability and regulatory capture via CMS renal denervation determinations. However, it assumes an aggressive multiple re-rating to 20 times forward earnings that conflicts with broader sovereign yield pressures.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.7%
Accurately identifies non-cyclical biological procedural demand as a shield against macroeconomic stagflation. It overstates diabetes hardware retention benefits by failing to recognize the near-term completion of the MiniMed split-off exchange offer.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.7%
Good synthesis of fixed-cost operational leverage and structural heart franchise stability. Yet it misses the specific structural mechanics of the share retirement in the pending split-off, treating portfolio separation more loosely than primary documentation warrants.
J.P. Morgan AI
The Titan
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.8%
Presents an aggressive growth thesis emphasizing hospital procurement lock-in. However, the path relies on heroic multiple expansion to 19 times and doubling enterprise value, largely dismissing serious competitive counter-offensives and ongoing product liability litigation risks.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.8%
Constructs an insightful narrative around clinical software integration into cath-lab hardware. However, the projected 98% five-year equity price trajectory is fundamentally disconnected from disciplined cash-flow discounting in an elevated sovereign yield regime.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Medtronic forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web37 available sources from this batch. The first 15 are shown below; expand to read the rest.
- Renal Denervation for Uncontrolled Hypertension | CMS cms.gov
- Document sec.gov
- mdt-20260424 sec.gov
- Medtronic plc - Form 10-Q - FY2026 sec.gov
- Medtronic plc - Form 8-K - FY2026 sec.gov
- Medtronic plc - Form 8-K - FY2026 sec.gov
- www.sec.gov sec.gov
- https://assets.hpra.ie/data/docs/default-source/product-updates/fsn/field-safety-notices/march-2026/sphere-9-catheter_medtronic-inc-_advice-regarding-changes-or-updates-made-to-instructions-for-use.pdf?sfvrsn=e2ba80ec_3 assets.hpra.ie
- Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance - BioSpace biospace.com
- Medtronic Diabetes to submit patch pump to FDA by fall 2026 drugdeliverybusiness.com
- Medtronic PLC (MDT) (Q1 2027) Earnings Call Highlights: Strong Revenue Growth and Raised ... finance.yahoo.com
- Medtronic launches exchange offer to split off MiniMed stake - Financial News financial-news.co.uk
- Medtronic (MDT) to Announce Q1 FY2027 Earnings on August 18 gurufocus.com
- Medtronic Diabetes Business Separation - iData Research idataresearch.com
- Earnings call transcript: Medtronic beats Q1 2026 estimates and lifts outlook By Investing.com investing.com
Show 22 more sources
- CMS finalizes renal denervation coverage that benefits Medtronic, Recor massdevice.com
- Medtronic Hugo Robotic Surgery System: New 2026 FDA-Cleared Challenger Enters US Market | Medaptly medaptly.com
- CMS grants NCD for renal denervation, benefiting Medtronic, Recor | MedTech Dive medtechdive.com
- Medtronic begins final steps to separate MiniMed | MedTech Dive medtechdive.com
- Medtronic receives FDA approval for renal denervation device | MedTech Dive medtechdive.com
- Medtronic’s Hugo surgical robot earns FDA clearance | MedTech Dive medtechdive.com
- Renal Denervation (RDN) Reimbursement | Medtronic medtronic.com
- Symplicity Spyral™ renal denervation system Overview ... medtronic.com
- Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias - Aug 6, 2026 news.medtronic.com
- Medtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted Surgery - Sep 1, 2026 news.medtronic.com
- Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc. - Sep 14, 2026 news.medtronic.com
- Medtronic News news.medtronic.com
- Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance - Sep 1, 2026 news.medtronic.com
- Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance - Sep 1, 2026 news.medtronic.com
- Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years - Jun 3, 2026 news.medtronic.com
- Press releases | Medtronic news.medtronic.com
- Medtronic Opens MiniMed Split-Off Exchange Offer With 7% Discount – Securities.io securities.io
- Medtronic (MDT) Stock Forecast & Analyst Price Targets stockanalysis.com
- Medtronic outlines MiniMed share exchange offer | MDT SEC Filing - Form 425 stocktitan.net
- Medtronic Launches Exchange Offer to Complete MiniMed Separation surgicalroboticstechnology.com
- Medtronic Advances Diabetes Spin-Off with Share Exchange - TipRanks.com tipranks.com
- FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures | Urology Times urologytimes.com
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2015-04-30–2026-04-30, 12 periods; Quarterly fiscal periods: 2023-10-31–2026-07-31, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.